ストックスクリーナーアプリを入手
2.36
1.72%
0.04
プレマーケット:
2.15
-0.21
-8.90%
前日終値:
$2.32
開ける：
$2.29
24時間の取引高:
223.69K
Relative Volume:
0.39
時価総額：
$19.09M
収益：
$1.73M
当期純損益:
$-23.50M
株価収益率:
-0.5403
EPS:
-4.3682
ネットキャッシュフロー:
$-19.37M
1週間 パフォーマンス:
-5.22%
1か月 パフォーマンス:
-26.62%
6か月 パフォーマンス:
-66.71%
1年 パフォーマンス:
-74.78%
1日の値動き範囲:
$2.10
$2.3695
1週間の範囲:
$2.0114
$2.50
52週間の値動き範囲:
$2.0114
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
名前
VolitionRX Ltd
セクター
電話
646 650 1351
住所
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
2.36 | 18.76M | 1.73M | -23.50M | -19.37M | -4.3682 |
TMO
Thermo Fisher Scientific Inc
|
446.03 | 170.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
165.99 | 117.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.68 | 42.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
334.93 | 34.57B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.74 | 31.91B | 7.07B | 1.29B | 993.00M | 4.5355 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 開始されました | Maxim Group | Buy |
| 2018-05-14 | 繰り返されました | The Benchmark Company | Buy |
| 2016-09-07 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-02-01 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
VolitionRX Ltd (VNRX) 最新ニュース
VolitionRx (VNRX) seeks approval to cut authorized shares and adopt 2026 equity plan - Stock Titan
TradingKey - TradingKey
Earnings Preview: VolitionRX to Report Financial Results Pre-market on May 15 - Moomoo
What to expect from VolitionRx’s May 15 Q1 2026 earnings call - Stock Titan
MSN Money - MSN
VolitionRx (VNRX) Advances Feline Cancer Detection Research with New Submission - GuruFocus
BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study - StreetInsider
A blood test for cat lymphoma showed 86% detection at 97% specificity - Stock Titan
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats - Sahm
VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights - Minichart
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRX Limited (VNRX) Investment Case | Q4 2025: Earnings UnderperformEV/EBITDA - Newser
VolitionRX | 10-K/A: Annual report (Amendment) - Moomoo
CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx (VNRX) Achieves Breakthrough in Sepsis Detection with New Test - GuruFocus
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Barchart.com
VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing - Minichart
VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split - Stock Titan
DISCLOSED: 5 Stocks Congress Just Bought (PC6HZG2Kcg) - Fathom Journal
Is VolitionRX Limited (VNRX) stock forming a clear pattern | Q4 2025: EPS Misses EstimatesFCF Yield - newser.com
VolitionRX | 8-K: Current report - Moomoo
VNRX Should I Buy - Intellectia AI
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRx receives NYSE American compliance plan approval - Investing.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan
VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan
D Boral Capital downgrades VolitionRx (VNRX) - MSN
VolitionRx launches online shop for recombinant nucleosomes By Investing.com - Investing.com Australia
VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside? - AD HOC NEWS
D. Boral Capital downgrades VolitionRX stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital Downgrades VolitionRX(VNRX.US) to Hold Rating - Moomoo
After building for 10 years, Volition puts nucleosomes up for sale online - Stock Titan
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and Compliance Data - Minichart
VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves - AD HOC NEWS
VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026 - Stock Titan
Volition approves 1-for-20 reverse stock split effective April 28, 2026 - TradingView
VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S. - AD HOC NEWS
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com Australia
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus
VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo
VolitionRX Ltd (VNRX) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
0.35%
大文字化:
|
ボリューム (24 時間):